Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J M Leonard

Showing results (51-60 of 69) with videos related to

Pageof 7
Sort By:
AIDS (London, England)|April 16, 1998
The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadirD J Kempf, R A Rode, Y Xu, et al.
Nature Medicine|February 14, 1998
Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferationN G Pakker, D W Notermans, R J de Boer, et al.
Virology|October 30, 1998
Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virusA Molla, S Vasavanonda, G Kumar, et al.
The Journal of Infectious Diseases|March 9, 1999
Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: relationships to host factors, cellular restoration, and virologic end pointsH Wu, D R Kuritzkes, D R McClernon, et al.
Antimicrobial Agents and Chemotherapy|May 1, 1997
Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjectsA Hsu, G R Granneman, G Witt, et al.
The Journal of Infectious Diseases|July 4, 1998
Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315M M Lederman, E Connick, A Landay, et al.
Earth and Space Science (Hoboken, N.J.)|October 12, 2020
Initial Orbit Determination and Event Reconstruction From Estimation of Particle Trajectories About (101955) BennuJ M Leonard, C D Adam, J Y Pelgrift, et al.
AIDS (London, England)|February 19, 1998
Decrease of HIV-1 RNA levels in lymphoid tissue and peripheral blood during treatment with ritonavir, lamivudine and zidovudine. Ritonavir/3TC/ZDV Study GroupD W Notermans, S Jurriaans, F de Wolf, et al.
The Journal of Infectious Diseases|December 23, 1999
Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic responseE Connick, M M Lederman, B L Kotzin, et al.
Antimicrobial Agents and Chemotherapy|March 1, 1997
Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavirD J Kempf, K C Marsh, G Kumar, et al.
Pageof 7

Showing results (51-60 of 69) with videos related to

Sort By:
Pageof 7
AIDS (London, England)|April 16, 1998
The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadirD J Kempf, R A Rode, Y Xu, et al.
Nature Medicine|February 14, 1998
Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferationN G Pakker, D W Notermans, R J de Boer, et al.
Virology|October 30, 1998
Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virusA Molla, S Vasavanonda, G Kumar, et al.
The Journal of Infectious Diseases|March 9, 1999
Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: relationships to host factors, cellular restoration, and virologic end pointsH Wu, D R Kuritzkes, D R McClernon, et al.
Antimicrobial Agents and Chemotherapy|May 1, 1997
Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjectsA Hsu, G R Granneman, G Witt, et al.
The Journal of Infectious Diseases|July 4, 1998
Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315M M Lederman, E Connick, A Landay, et al.
Earth and Space Science (Hoboken, N.J.)|October 12, 2020
Initial Orbit Determination and Event Reconstruction From Estimation of Particle Trajectories About (101955) BennuJ M Leonard, C D Adam, J Y Pelgrift, et al.
AIDS (London, England)|February 19, 1998
Decrease of HIV-1 RNA levels in lymphoid tissue and peripheral blood during treatment with ritonavir, lamivudine and zidovudine. Ritonavir/3TC/ZDV Study GroupD W Notermans, S Jurriaans, F de Wolf, et al.
The Journal of Infectious Diseases|December 23, 1999
Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic responseE Connick, M M Lederman, B L Kotzin, et al.
Antimicrobial Agents and Chemotherapy|March 1, 1997
Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavirD J Kempf, K C Marsh, G Kumar, et al.
Pageof 7